Bevacizumab for glioblastoma: current indications, surgical implications, and future directions
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab for glioblastoma: current indications, surgical implications, and future directions
Authors
Keywords
-
Journal
Neurosurgical Focus
Volume 37, Issue 6, Pages E9
Publisher
Journal of Neurosurgery Publishing Group (JNSPG)
Online
2014-12-01
DOI
10.3171/2014.9.focus14516
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
- (2017) Ulrich Herrlinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
- (2017) Eric T. Wong et al. Journal of the National Comprehensive Cancer Network
- Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma
- (2015) John de Groot et al. Oncotarget
- Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†
- (2014) B. Chauffert et al. ANNALS OF ONCOLOGY
- Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab
- (2014) William Magnuson et al. JOURNAL OF NEURO-ONCOLOGY
- Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation
- (2014) Alyssa Reiffel Golas et al. JOURNAL OF NEURO-ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
- (2014) David E. Piccioni et al. NEURO-ONCOLOGY
- Implications of bevacizumab discontinuation in adults with recurrent glioblastoma
- (2014) Mark D. Anderson et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma
- (2013) W. S. Carbonell et al. CANCER RESEARCH
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Disseminated progression of glioblastoma after treatment with bevacizumab
- (2013) Orin Bloch et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
- (2013) Emil Lou et al. Cancer Medicine
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
- (2012) M. DeLay et al. CLINICAL CANCER RESEARCH
- Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
- (2012) M. Nagane et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Impact of extent of resection for recurrent glioblastoma on overall survival
- (2012) Orin Bloch et al. JOURNAL OF NEUROSURGERY
- Bevacizumab and daily temozolomide for recurrent glioblastoma
- (2011) Annick Desjardins et al. CANCER
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors
- (2011) Samuel A. Goldlust et al. JOURNAL OF NEURO-ONCOLOGY
- An extent of resection threshold for newly diagnosed glioblastomas
- (2011) Nader Sanai et al. JOURNAL OF NEUROSURGERY
- A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
- (2011) Ashwatha Narayana et al. JOURNAL OF NEUROSURGERY
- Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
- (2011) L. B. Nabors et al. NEURO-ONCOLOGY
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
- (2011) J. L. Clarke et al. NEURO-ONCOLOGY
- Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
- (2011) W. B. Pope et al. NEUROLOGY
- Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment
- (2011) Aaron J. Clark et al. NEUROSURGERY
- Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival
- (2011) Jan-Karl Burkhardt et al. World Neurosurgery
- Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas
- (2010) Marc C. Chamberlain CANCER
- American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section
- (2010) Patrick Y Wen Expert Review of Anticancer Therapy
- Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation
- (2010) Mackenzie C. McGee et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Up-front temozolomide in elderly patients with glioblastoma
- (2010) Florence Laigle-Donadey et al. JOURNAL OF NEURO-ONCOLOGY
- Impact of bevacizumab chemotherapy on craniotomy wound healing
- (2010) Aaron J. Clark et al. JOURNAL OF NEUROSURGERY
- Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
- (2010) B. J. Scott et al. NEURO-ONCOLOGY
- Sorafenib exerts anti-glioma activity in vitro and in vivo
- (2010) Markus D. Siegelin et al. NEUROSCIENCE LETTERS
- Treating IIA/B Seminoma With Combination Carboplatin and Radiotherapy
- (2009) Duncan C. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
- (2009) Christopher G. Willett et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Costly Cancer Drugs Trigger Proposals To Modify Clinical Trial Design
- (2009) C. Schmidt JNCI-Journal of the National Cancer Institute
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION
- (2009) MAJID ABRISHAMI et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
- (2008) Felix Bokstein et al. CANCER
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- ACNU-based chemotherapy for recurrent glioma in the temozolomide era
- (2008) Caroline Happold et al. JOURNAL OF NEURO-ONCOLOGY
- Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
- (2008) Sheikh A. Ali et al. JOURNAL OF NEUROSURGERY
- Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions
- (2008) G. Sinha JNCI-Journal of the National Cancer Institute
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started